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Background: Cancer cells can employ telomerase or the alternative lengthening of telomeres (ALT) pathway for
telomere maintenance. Cancer cells that use the ALT pathway exhibit distinct phenotypes such as heterogeneous
telomeres and specialised Promyelocytic leukaemia (PML) nuclear foci called APBs. In our study, we used wild-type
PML and a PML mutant, in which the coiled-coil domain is deleted (PML C/C-), to investigate how these proteins
can affect telomere maintenance pathways in cancer cells that use either the telomerase or ALT pathway.
Results: Stable over-expression of both types of PML does not affect the telomere maintenance in the ALT cells.
We report novel observations in PML over-expressed telomerase-positive MCF7 cells: 1) APBs are detected in
telomerase-positive MCF7 cells following over-expression of wild-type PML and 2) rapid telomere elongation is
observed in MCF7 cells that stably express either wild-type PML or PML C/C-. We also show that the telomerase
activity in MCF7 cells can be affected depending on the type of PML protein over-expressed.
Conclusion: Our data suggests that APBs might not be essential for the ALT pathway as MCF7 cells that do not
contain APBs exhibit long telomeres. We propose that wild-type PML can either definitively dominate over
telomerase or enhance the activity of telomerase, and PML C/C- can allow for the co-existence of both telomerase
and ALT pathways. Our findings add another dimension in the study of telomere maintenance as the expression of
PML alone (wild-type or otherwise) is able to change the dynamics of the telomerase pathway.Background
Telomeres are specialised chromatin structures capping
the ends of chromosomes [1]. They consist of TTAGGG
repeats and function to protect the ends of the DNA.
Human telomeres in somatic cells lose about 50 to 150
base pairs with each round of cellular division. When
telomeres shorten to a critical length, cells will enter a
state of permanent growth arrest termed as replicative
senescence. Cellular senescence limits the proliferative cap-
acity of cells and this suppresses tumourigenesis [2]. To* Correspondence: phsmph@nus.edu.sg
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cancer cells maintain telomeres through the activation of
the telomerase enzyme. Some cancer cells also use the
lesser-known telomere maintenance pathway-the Alterna-
tive Lengthening of Telomeres pathway, ALT [3,4].
Cancer cells that employ the ALT pathway for telomere
maintenance exhibit distinct hallmarks from cells that use
telomerase [5]. These cells exhibit heterogeneous telo-
meres, with length varying between 3 kb and 50 kb [5-7].
ALTcancer cells also contain ALT-associated promyelocytic
leukaemia (PML) bodies, termed APBs [5]. While APBs
contain normal constituents of PML bodies such as PML
and Sp100 proteins, they also contain telomeric DNA and
telomere-associated proteins such as telomere-repeat bind-
ing factors (TRF) 1 and 2 [8]. APBs are unique to ALT cells
as they are not present in normal and telomerase-positive
cells [9]. As APBs and heterogeneous telomere length aretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A) Schematics of the PML protein depicting its functional domain. RING indicates the RING finger domain while B1 and B2
represent the B-boxes. S indicates SUMO protein modification of the lysine residues at the indicated positions (boxed in red). B) Chromatographs
depicting successful mutations of the lysine sites to arginine in the PML protein through PCR mutagenesis. Chromatograms of (i) PML K65R, (ii)
K160R, (iii) K490R, (iv) K65/160R, (v) K65/490R, (vi) K160/490R and (vii) K65/160/490R plasmids. The boxed codons indicate the location of the
successful mutations. C) Western blot analysis showed that PML K160/490R double and K65/160/490R triple mutants are not modified by SUMO.
JFCF-6/T.1R cells were transfected with the indicated plasmids and cells were harvested 48 h after transfection in the presence and absence of
NEM. The use of NEM preserves SUMO-conjugated proteins. The SUMO protein adds about 10–20 KDa in molecular weight to that of the protein
in its native form. The slower migrating band is indicative of SUMO-modified PML. All PML constructs are HA-tagged and the blots were probed
with the indicated antibodies (anti-HA: 1:5000, anti-actin: 1:2000). Actin was used as a loading control.
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maintenance, these two phenotypes are used as definitive
hallmarks for ALT cells [10].
There exist uncertainties as to whether APBs are truly
involved in the ALT pathway or if they are simply by-
products of the pathway [11]. APBs have been proposed
to be the sites of telomeric recombination by virtue of
the detection of telomeric DNA, and DNA repair and
recombination proteins within them [8,12]. This sug-
gests APBs as important sites for the co-localisation of
proteins involved in ALT and reinforce the hypothesisthat telomeric recombination is the mechanism of telo-
mere elongation in the ALT pathway [5,13,14]. However,
the absence of APBs in some cells that possess
telomerase-independent telomere maintenance mechan-
isms illustrates that APBs might not be absolutely essen-
tial for the ALT pathway [15,16]. Still, APBs are believed
to be tightly correlated to the ALT pathway as important
mediators for the process, as studies have shown the ap-
pearance and disappearance of APBs with the onset and
inhibition of ALT pathway, where the inhibition of APBs
caused telomere shortening [8,17,18].
Figure 2 (See legend on next page.)
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Figure 2 The formation of APBs is independent of the SUMOylation of the PML protein. All PML KR mutants can form APBs in ALT cells. A)
U2OS and B) JFCF-6/T.1R cells were transfected with (i) empty vector PCI Neo, (ii) wild-type PML, (iii) PML K65R, (iv) PML K160R, (v) PML K490R, (vi)
PML K65/160R, (vii) PML K65/490R, (viii) PML K160/490R and (ix) PML triple K65/160/490R plasmids. (x) Graphs depicting percentage of cells
expressing APBs. At least 50 cells were scored and the results were summarised from at least three independent experiments. Values represent
the mean ± SD. All PML plasmids are HA-tagged. In PCI Neo transfected cells (i), detection of APBs was based on co-localisation of endogenous
PML and TRF2. Arrows indicate detection of APBs, defined as the co-localisation of PML with TRF2. Immunofluorescence was performed 48 h
after transfection and the indicated antibodies were used. DAPI was used for nuclear staining. Images were captured with confocal microscopy at
100 X magnification. * indicates p < 0.05.
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clear bodies. There are three small ubiquitin-like modi-
fier (SUMO) binding sites in PML, at lysines 65, 160 and
490 [19]. As SUMOylation of PML has been shown to
affect the formation of PML nuclear bodies [20], such
modification is deemed to be important for the forma-
tion of PML nuclear bodies [19-21]. However, a SUMO
interaction motif present in PML, [22] allows it to tether
to SUMO independently of the three SUMO lysine sites.
It is thus likely that the SUMO-modification of PML is
also important for APBs formation, although, to the best
of our knowledge, the importance of the SUMOylation
of PML in the formation of APBs and thereby in the
ALT pathway has not been studied. The PML protein
contains a coiled-coil domain, which has been shown to
be important in the initiation of the nucleation and
oligomerisation processes that are critical in the forma-
tion of PML nuclear bodies [21,23,24]. This domain is
also required for the critical step in the SUMOylation
process of binding of Ubc9, a SUMO conjugation en-
zyme, to PML [24]. Thus, the coiled-coil domain of
PML is probably also important for the formation of
APBs. However, it is unclear if the coiled-coil domain
can affect the ALT pathway in part due to its influence
on APBs formation.
In our study, we investigated if PML affects the forma-
tion of APBs through SUMOylation, the importance of
APBs in the ALT pathway, and if PML has any impact
on the telomerase pathway. We expressed SUMO-
defective and coiled-coil domain deficient PML in ALT
cells to determine if these exogenous proteins can form
APBs. Over-expression of both wild-type and mutant
PML was also performed in telomerase-positive MCF7
cells to study if they affect telomere maintenance regu-
lated by telomerase. Here, we present our novel finding of
the detection of APBs in telomerase-positive MCF7 cells
following stable expression of wild-type PML. Our study
also showed for the first time that while the expression of
wild-type and mutant PML did not affect the telomere
phenotype of the ALT cells, they brought about a dramatic
elongation of the telomeres in the telomerase-positive
cells. Interestingly, such elongation could occur in the ab-
sence of APBs. Elongation of telomeres in MCF7 cells was
accompanied with changes in telomerase activity and thisis apparently dependent on the type of PML over-
expressed. Our study thus suggests that while APBs might
definitively promote the onset of the ALT pathway, telo-
mere elongation may proceed in the absence of APBs.
Results
To determine the effects of SUMO-defective PML on
the formation of APBs, we first generated PML KR plas-
mids where the SUMO lysine sites were mutated to ar-
ginine. There are three SUMO attachment sites in PML
[19], at lysine 65, 160 and 490 (Figure 1A). A total of
seven mutants were generated (Figure 1B); three single
mutants containing mutation at each lysine site
(Figure 1B i-iii), three double mutants containing muta-
tion at two lysine sites (Figure 1B iv-vi) and one triple
mutant containing mutations at all the three sites
(Figure 1B vii). These mutants are hence termed PML
KR mutants. All seven mutants, in addition to the wild-
type PML protein, are tagged with haemagglutinin (HA),
to allow for the detection of exogenous PML proteins.
N-ethylmaleimide (NEM) is commonly used to pre-
served SUMO-conjugated proteins [25], allowing for
their detection in western blots. Thus protein lysates
were harvested in the presence and absence of NEM. As
SUMO add about 20 kDa in molecular weight, SUMO-
modified PML appears as the slower migrating band. All
PML KR mutants remained modifiable by SUMO except
for the K160/490R double mutant and the triple mutant
(Figure 1C).
We then investigated the effects of PML KR mutants
on the formation of APBs in ALT cells. In our study,
APBs are defined by the co-localisation of PML with
TRF2. As the PML constructs used in this study are
HA-tagged, anti-HA and anti-TRF2 antibodies were
used for co-immunofluorescence. The use of anti-HA
antibodies eliminates confusion between endogenous
and exogenously introduced PML. The ALT-positive
U2OS and JFCF-6/T.1R cells were transiently transfected
with wild-type PML and PML KR mutants (Figure 2).
Co-localisation of PML and TRF2 was detected with all
PML KR mutants, suggesting that the formation of APBs
is independent on the SUMOylation of the PML protein.
The PML protein contains a coiled-coil domain which
is critical for the nucleation process in the formation of
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is also implicated in the SUMOylation of PML whereby
the loss of the domain leads to a loss of SUMOylation of
the PML-retinoic acid receptor alpha fusion protein
[24]. We first verified that the PML protein lacking the
coiled-coil domain (henceforth referred to as PML C/C-)
does not exhibit a higher molecular weight bandFigure 3 (See legend on next page.)indicative of SUMO-PML (Figure 3A) in three different
cell lines. We then questioned whether the coiled-coil
domain might affect the formation of APBs in ALT cells.
To this end, we performed transient transfections of
wild-type PML and PML C/C- plasmids into U2OS,
JFCF-6/T.1R and MCF7 cells to carry out immunofluor-
escence studies (Figure 3B-D). We observed that the
(See figure on previous page.)
Figure 3 A) PML C/C- is not modified by SUMO in (i) U2OS, (ii) JFCF-6/T.1R and (iii) MCF7 cells. U2OS and JFCF-6/T.1R are established ALT
cell types while MCF7 is a telomerase-positive cell line. The cells were transfected with the indicated plasmids. Cell lysates were harvested in the
presence and absence of N-ethylmaleimide (NEM) 48 h after transfection and protein expression was detected with western blot analysis. Wild-
type PML is HA-tagged while PML C/C- is FLAG-tagged. Blots were probed with the indicated antibodies. B-actin was used as a loading control.
B) APBs are ALT-specific. Endogenous APBs were detected in (i) U2OS and (ii) JFCF-6/T.1R cells but not in (iii) MCF7 cells. PML antibodies were
used to detect endogenous PML. (C) Transiently over-expressed HA-tagged wild-type PML co-localized with TRF2 in (i) U2OS and (ii) JFCF-6/T.1R
but not in non-ALT (iii) MCF7 cells. (D) Transiently over-expressed FLAG-tagged coiled-coil domain deficient PML mutant did not form distinct
nuclear bodies in all three cell-lines, (i) U2OS, (ii) JFCF-6/T.1R, (iii) MCF7. E) Graph depicting the percentage of cells expressing APBs. At least 100
cells were scored and the results were summarized from at least three independent experiments. Values represent the mean ± SD. APBs are
defined by the co-localisation of PML with TRF2 and are indicated by arrows. PCI Neo was used as an empty vector control. DAPI was used for
visualisation of the nucleus and the indicated antibodies were used. Images were captured with confocal microscopy at 100 X magnification. *
indicates p < 0.05.
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cells co-localised with TRF2, giving rise to APBs. How-
ever, the over-expressed PML in MCF7 cells did not
form APBs even though distinct PML foci were formed.
It should be noted that while TRF2 foci were easily
observed in ALT cells, they were not readily detected in
MCF7 cells. Interestingly, over-expression of PML C/C-
in all the three cell types did not form any PML distinct
foci that allowed for the formation and observation of
APBs.
In this study, we wanted to investigate how the pre-
vention of APBs formation can affect telomere mainten-
ance through the ALT pathway. As changes in telomere
length are more prominent in long-term studies, we gen-
erated U2OS and MCF7 cells that express wild-type
PML and PML C/C- stably. For each of the empty vec-
tor pCI Neo, wild-type PML and PML C/C- constructs,
two clones of U2OS and MCF7 cells were randomly
selected and used in subsequent studies. Immunofluores-
cence was performed on the clones to determine if the
long-term expression of wild-type PML and PML C/C-
affects the formation of APBs. In the two U2OS clones
that stably express wild-type PML, U2OS PML STC20
and PML STC21, PML continued to form distinct foci
that co-localised with TRF2 to form APBs (Figure 4A).
In the two U2OS clones stably expressing PML C/C-,
U2OS PML C/C- STC20 and PML C/C- STC22, the
stable over-expression of PML C/C- did not lead to the
formation of distinct foci to result in APBs.
Interestingly, in the two MCF7 clones that stably express
wild-type PML, different phenotypes were observed
(Figure 4B). In MCF7 PML STC7, while PML formed dis-
tinct foci, no APBs were observed. However, in MCF7 PML
STC10, the distinct PML foci formed co-localised with
TRF2 to give rise to APBs. To the best of our knowledge,
this is the first study to show the presence of APBs follow-
ing the stable expression of wild-type PML in MCF7 cells.
As APBs are thought to be essential for the ALT
pathway, we speculated that the absence of APBs in U2OS
PML C/C- clones and the presence of APBs in MCF7 cells
might affect telomere length in these cells. We then lookedat the telomere status in the clones for 20 passages, with
telomere length analysis performed at every 5th passage
(Figure 5). The mean telomere length was measured
through Southern blot analysis of terminal restriction frag-
ments. In both U2OS PML STC20 (Figure 5A) and PML
STC21 (Figure 5B) clones, wild-type PML did not positively
affect telomere length. Similarly, PML C/C- did not nega-
tively affect telomere length in U2OS PML C/C- STC20
and PML C/C- STC22 clones.
In MCF7 cells, the stable expression of wild-type PML
in MCF7 PML STC7 did not affect telomere length
(Figure 5C). However, in MCF7 PML STC10, the long-
term expression of wild-type PML led to a dramatic in-
crease in telomere length (Figure 5D). Telomere length
in MCF7 PML STC10 cells increased from about 3000
base pairs to 8000 base pairs. It is noteworthy that APBs
were observed in MCF7 PML STC10 cells as mentioned
above (Figure 3B). Interestingly, the stable expression of
PML C/C- led to telomere elongation in both MCF7
PML C/C- STC7 and STC22 clones. While the telomere
length in MCF7 PML C/C- STC22 increased from 3000
to 9000 base pairs, telomere length doubled in MCF7
PML C/C- STC7. It should also be noted that telomere
length phenotypes in MCF7 PML STC10 and PML C/C-
STC22 are reminiscent of that in ALT cells. We hereby
report, for the first time, that stably expressed wild-type
PML and PML C/C- can bring about a rapid increase in
telomere length in MCF7 cells.
We then studied the telomerase activity in the MCF7
clones to determine if there might be any changes to its
inherent telomere maintenance mechanism resulting
from the over-expression of the PML proteins. Telomer-
ase activity was compared to the cells stably expressing
the empty vector, PCI Neo (Figure 6A). In MCF7 PML
STC7 cell type where there was no apparent telomere
length changes, telomerase activity was more than
doubled compared to that in the empty vector control
cells. However, in MCF7 PML STC10, wherein there
was a rapid increase in telomere length, the telomerase
activity was significantly reduced. This suggests a reduc-
tion in the role of the telomerase enzyme in maintaining
Figure 4 (See legend on next page.)
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Figure 4 Immunofluorescence studies of stably-expressed wild-type PML and PML C/C- in U2OS and MCF7 cells. (A) Endogenous APBs
were detected in (i) U2OS PCI Neo STC6 and (ii) PCI Neo STC8 clones. APBs were detected in (iii) U2OS PML STC20 and (iv) PML STC21 clones
which stably express wild-type PML. APBs were not formed with the stable expression of PML C/C- in (v) U2OS PML C/C- STC20 and (vi) PML C/C-
STC22 clones. (vii) Graph depicting percentage of U2OS cells expressing APBs. (B) Novel detection of APBs in MCF7 cells stably expressing wild-
type PML. APBs were not present in (i) MCF7 PCI Neo STC1 and (ii) STC4 clones. No APBs were detected in (iii) MCF7 PML STC7 clone but stably-
expressed wild-type PML formed distinct foci that co-localized with TRF2 to form APBs in (iv) PML STC10 clone. PML C/C- did not form APBs
when expressed stably in MCF7 cells, (v) PML C/C- STC7 and (vi) PML C/C- STC22. (vii) Graph depicting percentage of MCF7 cells expressing APBs.
At least 100 cells were scored and the results were summarized from at least three independent experiments. Values represent the mean ± SD.
Wild-type PML is HA-tagged while PML C/C- is FLAG-tagged. APBs are defined by the co-localisation of PML with TRF2 and are indicated by
arrows. DAPI was used for visualisation of the nucleus and the indicated antibodies were used. Images were captured with confocal microscopy
at 100 X magnification. * indicates p < 0.05.
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activity increased in MCF7 PML C/C- STC7 and STC22
clones, both of which demonstrated telomere elongation.
Collectively, our data suggests that the stable expression
of wild-type PML and PML C/C- in telomerase-positive
MCF7 cells affects the inherent telomere maintenance
mechanism. The changes could result from a switch in
the pathway utilised, from a dominant telomerase path-
way to the ALT pathway, or to a state of co-existence of
the two pathways of telomere maintenance.
As it appears that the pathway of telomere mainten-
ance in MCF7 cells is affected by the stable expression
of wild-type PML and PML C/C-, we sought to deter-
mine the clinical implications of such changes, if any. To
this end, we used doxorubicin and tamoxifen, which are
being used in the clinics for breast tissue malignancies
[26,27], to study the cell viability of the MCF7 clones
following 24 h of treatment with 1 μM of doxorubicin or
10 μM of tamoxifen (Figure 6B). In addition to the
MCF7 cells being more sensitive to doxorubicin than to
tamoxifen, it appears that MCF7 PML STC10 and
MCF7 PML C/C- STC22 cells, in which rapid telomere
elongation is observed, are slightly more sensitive to
doxorubicin. Our results suggest that a change in telo-
mere maintenance mechanism might affect the suscepti-
bility of cancer cells to therapeutic compounds.Discussion
As APBs are highly specific to cancer cells utilising the ALT
pathway for telomere elongation, they could be potentially
useful tools in novel anti-cancer drug discovery. While the
exact extent of the requirement and involvement of APBs
in the initiation and propagation of the ALT pathway is un-
clear, APBs are deemed as essential components for the
pathway. While the role of APBs has not been studied in
detail, it is certain that the PML protein is required for the
formation of APBs [20].
In the present study, wild-type PML and a PML mu-
tant, in which the coiled-coil domain (PML C/C-) has
been deleted, were expressed in ALT and telomerase
positive cells to determine if they can affect both typesof cells which utilise distinct telomere maintenance
mechanisms. The stable over-expression of wild-type
PML and PML C/C- in the ALT cell type, U2OS, did not
result in any changes in APBs formation and in telomere
length. In addition, the over-expressed PML C/C- could
not perturb the endogenous PML in the U2OS cells to
affect the inherent telomere maintenance pathway. This
suggests that there is possibly an optimal level of PML
in the ALT cells that could sustain the ALT pathway. We
also showed that the coiled-coil domain of PML is
required for the formation of distinct PML foci and this
is consistent with published reports [21,23,24]. When
PML does not form distinct nuclear foci, no APBs were
observed in our study.
We report for the first time that the over-expression
of wild-type PML and PML C/C- in telomerase positive
MCF7 cells led to rapid telomere elongation. Wild-type
PML formed APBs in MCF7 cells stably expressing the
protein and the cells demonstrated a corresponding
rapid increase in telomere length. In MCF7 cells, while
PML C/C- does not form APBs, the protein can also re-
sult in telomere elongation. Our data suggests that the
stable expression of wild-type PML could possibly bring
about two greatly differing phenotypes in MCF7 cells.
Wild-type PML could possibly either cause a heightened
activity of the telomerase enzyme or it could form APBs
in MCF7 cells and bring about rapid elongation of telo-
meres. The latter suggestion would add on to the exist-
ing knowledge that the occurrence of the ALT pathway
is tightly correlated with the presence of APBs [18,28].
However, the stable expression of PML C/C- in MCF7
cells also led to rapid telomere elongation and this hap-
pened in the absence of APBs. This observation thus
offers the view that APBs might not be absolutely essen-
tial for the ALT pathway. Indeed, it has been reported
that some cancer cells exhibit telomere maintenance
mechanism that is telomerase-independent which occurs
in the absence of APBs [15,16]. It is noted that while
telomere length increment in PML C/C- STC 22 cells
is comparable to that in PML STC10, there is gradual
accumulation of longer telomeres in the former. We
postulate that while wild-type PML could elicit an all-or-
Figure 5 (See legend on next page.)
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Figure 5 Terminal restriction fragment analysis coupled with Southern blot was used for telomere length analysis. The stable over-
expression of wild-type PML and PML C/C- did not affect telomere length in U2OS cells. A) (i) Southern blot analyses of telomere length in U2OS
PCI Neo STC6, PML STC20 and PML C/C- STC20. (ii) Graphical representation of telomere length of clones in (A) (i). B) (i) Southern blot analyses of
telomere length in U2OS PCI Neo STC8, PML STC21 and PML C/C- STC22. (ii) Graphical representation of telomere length of clones in (B) (i).
Telomere length changes were observed in MCF7 cells following stable expression of wild-type PML and PML C/C-. C) (i) Southern blot analyses
of telomere length in MCF7 PCI Neo STC1, PML STC7 and PML C/C- STC7. (ii) Graphical representation of telomere length of clones in (C) (i). D)
Southern blot analyses of MCF7 PCI Neo STC4, PML STC10 and PML C/C- STC22. (ii) Graphical representation of telomere length of clones in (D)
(i). Genomic DNA was obtained from the cells at every 5th passage until the 20th passage. Genomic DNA was digested with HinfI and RsaI and
the digested DNA was resolved on an agarose gel. Southern blot analysis was carried out using the TeloTAGGG telomere length assay kit
according to manufacturer’s protocol (Roche). The smears represent the telomeres detected and grey lines indicate the mean telomere length as
analysed with Kodak Imager.
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sess an unknown quality that allows the cells expressing
it to exhibit telomere lengthening while bypassing the
requirement for APBs. However, it is possible that PML
C/C- might not bring about a rapid increment in telo-
mere length compared to the wild-type protein, and it
might require more time for the accumulation of longer
telomeres. More work definitely has to be done to deter-
mine if similar results could be obtained in other
telomerase-positive cell types and to elucidate the mo-
lecular players involved in the switch in the telomere
maintenance mechanisms. We also acknowledge that
our observed phenotypes could be subjected to clonal
specificity. It is, however, clear that the over-expression
of either wild-type PML or the PML C/C- can definitely
affect the telomere maintenance pathway in telomerase-
positive MCF7 cells while not significantly disrupting
that in ALT-positive U2OS cells.
Finally, our finding that the MCF7 cells with signifi-
cantly longer telomeres, PML STC10 and PML C/C-
STC22, displayed enhanced sensitivity towards doxo-
rubicin implies that certain compounds could exhibit se-
lectivity towards cells with extremely long telomeres. In
light of the development of the use of telomerase inhibi-
tors in cancer therapy [29], there is the possibility of the
emergence of telomerase inhibitor-resistant cells which
could switch to ALT pathway, thereby ending up with
unusually long telomeres. More studies are needed to
determine whether unusually long telomeres could in-
deed be a drug target in cancer cells that utilise the ALT
pathway and in cells that have demonstrated a possible
switch in the telomere maintenance mechanism. In
addition, the use of more advanced techniques, such as
Q-FISH (quantitative fluorescence in situ hybridisation)
and STELA (single telomere length analysis), in such
studies would be advantageous in determining the actual
changes in telomere length that might have occurred
during and after the treatment process.
Our observations suggest that APBs might not be essen-
tial for the ALT pathway, although its presence could
make the microenvironment favourable for the pathway.
In addition, the PML protein could be a very importantprotein for the ALT pathway and its role might not be
confined to that of APBs formation alone. As such, the
PML protein could be a new investigational target in the
study of the ALT pathway. It would be interesting to study
if there is a correlation between PML expression and tel-
omerase levels and activity in cancer tumours. Further
work in other telomerase positive cell lines (multiple
clones) and tumours will help to clarify of the role of PML
in influencing the existing telomerase pathway.
Methods
Cell culture, transfection and expression vectors
U2OS, ALT-positive osteosarcoma cells (ATCC) and
JFCF-6/T.1R cells (gift from Prof. R. Reddel) [8] were
grown in 5A McCoy’s medium, supplemented with 10%
foetal bovine serum and L-glutamine. Cells were sub-
cultured when 80% confluent with trypsin-EDTA. Cells
were maintained in 37°C incubator with 5% atmospheric
CO2. Cells were seeded at 70–80% confluency for
transfections.
Lipofectamine 2000 (Invitrogen) was used for transfec-
tion of all cell-lines. Lipofectamine 2000 was used at a 1:3
ratio, with 3 μl used with every 1 μg of plasmid. Briefly,
Lipofectamine 2000 reagent was diluted in Opti-MEM
(Invitrogen) and added to plasmids to be used for transfec-
tion. The mixture was allowed to incubate for 45 min, after
which the entire mixture was added to cell cultures. Cells
were harvested 24, 48 or 72 h after transfection. The same
procedure was followed for stable transfections except that
48 h after transfection, the selection antibiotic, G418, was
added for 14–21 days. The mixed population obtained
after 14–21 days of selection was then seeded at 1000 cells
per 15-cm plate and colonies were allowed to form in the
presence of G418. When colonies were visible, they were
picked and amplified. Western blot was performed to en-
sure the stable integration of the plasmid transfected. Cells
were maintained in media containing G418.
Wild-type PML (isoform IV) and PML C/C- expres-
sion vectors were used in this study. Wild-type PML and
PML KR mutants are tagged with haemagglutinin (HA)
while the coiled-coil deficient PML is tagged with the
FLAG peptide.
Figure 6 A) Telomerase activity in MCF7 cells is affected by wild-type PML and PML C/C-. (i) Telomerase activity in MCF7 PML STC7 and
PML C/C- STC7 cells are increased compared to the MCF7 PCI Neo STC1 cells. (ii) Telomerase activity was reduced in MCF7 PML STC10 while PML
C/C- STC22 demonstrated increased activity. Telomerase activity was measured using the TRAPezeXL Telomerase Detection kit according to
manufacturer’s protocol (Millipore). Telomerase activity is represented in terms of percentage of the total product generated (TPG) as measured
by the assay. B) MCF7 clones demonstrating extremely long telomeres (Figure 5D i) exhibited enhanced susceptibility towards doxorubicin. (i)
There were no significant differences in the susceptibility of MCF7 PML STC7 and PML C/C- STC7 towards doxorubicin or tamoxifen. (ii) MCF7
PML STC10 and PML C/C- STC22 demonstrated an increased sensitivity toward doxorubicin. Cell viability was measured using the crystal violet
assay. Cells were treated with either 1 μM of doxorubicin or 10 μM of tamoxifen for 24 h. DMSO was used as a vehicle control. At least three
independent experiments were performed. *** indicates p < 0.01.
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There are three established lysine sites in PML which
are modifiable by SUMO; lysines at position 65, 160 and
490. PCR mutagenesis was performed to generate the
single PML KR mutants using the wild-type PML vector.
For generation of the double mutants, the plasmids con-
taining single mutants were used. For generation of the
triple mutant, the plasmids containing double mutations
were used. The mutations to be introduced by the primers
are underlined accordingly. For mutating lysine at position
65 to arginine, the sequence of the forward primer used
was 50 CAGGCGGAAGCCCGATGCCCGAAGCTG 30
and the reverse primer was 50 CAGCTTCGGGCATCGG
GCTTCCGCCTG 30. For mutating lysine at position 160,
the forward primer used was 50 CAGTGGTTCCTCCGT
CACGAGGCCCGG 30 and the reverse primer used was 50
CCGGGCCTCGTGACGGAGGAACCACTG 30. For mu-
tating lysine at position 490, the forward primer used was
50 AGGAAGGTCATCCGCATGGAGTCTGAG 30 and thereverse primer used was 50 CTCAGACTCCATGCGGATG
ACCTTCCT 30. PCR was carried out with the wild-type
PML plasmid, the forward and reverse primers, dNTPs and
Pfu Turbo enzyme (Invitrogen). The PCR conditions are
as follow; for initialization, 95°C for 30 s, denaturation at
95°C for 30 s, annealing at 55°C for 1 minute and exten-
sion at 68°C for 30 min for 18 cycles. The PCR products
were then digested with DpnI to digest the parental wild-
type PML plasmid. The plasmids were then sequenced
with the ABI PRISM Big Dye Reaction Terminator
CycleSequencing Kit version 3.1 (Applied Biosystems)
to verify the success of the mutagenesis process.Western blotting
Cells were dislodged using trypsin-EDTA and lysed with
lysis buffer containing PMSF, DTT and complete-MINI
tablet (Roche). Equal amounts of proteins were loaded
into 10% SDS-polyacrylamide gel and separated at 220 V
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nitrocellulose membrane via semi-dry transfer. Mem-
branes were then placed in blocking solution containing
milk and TBS and subsequently incubated with primary
antibodies at 4°C overnight. On the second day, the
membrane was incubated with secondary antibodies for
one hour at room temperature. Proteins were then
detected with the use of SuperSignal West Femto sub-
strate (Thermo Scientific). Antibodies used were anti-HA
(1:2000; Covance), anti-FLAG (1:6000; Sigma), anti-actin
(1:2000; Sigma), anti-SUMO (1:500; Zymed) antibodies.
Immunofluorescence
Ten thousand cells were seeded onto a coverslip and
allowed to attach overnight. After cells were fixed with 4%
paraformaldehyde for 10 min at room temperature, they
were permeabilised with 0.1% Triton X-100. After 10 min
of incubation with 3% BSA, cells were then incubated with
primary antibodies for 1 h at room temperature and sub-
sequently, with fluorescent secondary antibodies for an-
other hour at room temperature. After a series of
washing, the slides were left to dry. Thereafter, mounting
media containing DAPI (Vectashield) was added and cov-
erslips were then mounted onto glass slides and examined
under confocal fluorescent microscope. Images were cap-
tured at the 100X magnification. Primary antibodies used
were anti-PML (1:100; PG-M3, Santa Cruz), anti-TRF2
(1:100; Santa Cruz), anti-HA (1:5000; Covance), anti-
FLAG (1:10000; Sigma). Secondary antibodies used were
Alexa Fluor 488 (1:1000; Invitrogen) and Alexa Flour 594
(1:1000; Invitrogen).
Terminal restriction fragment analysis and southern blot
TeloTAGGG Telomere length assay kit (Roche) was
used for the measurement of telomere length. Instruc-
tions were followed per manufacturer’s kit. Briefly, gen-
omic DNA was digested with HinfI and RsaI for 10–
15 min in 37°C water bath. Digested genomic DNA was
then separated in 0.7% agarose gel for at 60 V for about
six hours. The gel was then placed in an acidic solution
and after neutralisation, the gel was placed in a ‘sand-
wich’ for southern transfer of DNA onto a membrane
via capillary action. Following overnight transfer, DNA
on membrane was fixed by UV and incubated with DIG
labelled anti-TTAGGG probe at 42°C for at least 4 h.
Visualisation was done with the anti-DIG chemilumines-
cent substrate, CDP-STAR. The average telomere length
was determined by comparison with the molecular
weight standard using Kodak Imager.
Telomerase activity assay
Telomerase activity was determined with the TRAPeze
XL kit from Chemicon. The protocol per manufacturer’s
instructions was followed. Briefly, protein lysate wasprepared for a PCR reaction with AmplifluorW primers.
The thermocycler was set for a 4-step PCR as follows;
94°C/30 s, 59°C/30 s, 72°C/1 min for 36 cycles followed
by a 72°C/3 min extension step and then 55°C/25 min,
concluding with a 4°C incubation. Following the PCR re-
action, equal amounts of the reaction mix consisting of
10 mM Tris–HCl pH 7.4, 0.15 M NaCl and 2 mM MgCl2
was added to the PCR reaction mixture. The fluorescent
readout was obtained with Magellan, with excitation/
emission parameters for fluorescein set at 495 nm/516 nm
and sulforhodamine set at 600 nm/620 nm. Analysis was
performed following manufacturer’s instructions.
Crystal violet cell viability assay
Crystal violet intercalates into double-stranded intact
DNA and was used to assess the viability of the cells after
treatment with doxorubicin and tamoxifen. Cells were
seeded at 0.1 × 106 cells in 6-wells plate and allowed to at-
tach overnight. Cells were then treated with either doxo-
rubicin or tamoxifen for 24 and 48 h. After the desired
treatment duration, media was removed and cells were
washed with PBS twice. 500 μl of crystal violet solu-
tion was added to the wells and incubated at room
temperature for 15 min. After a series of washes, the cells
were then dissolved in 0.1% triton-× 100 (diluted with
PBS) and the absorbance was measured at 595 nm.
Statistical significance
Student’s t-test (Graphpad Prism) was used to assess
statistical significance.
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